core outlook mostli unchang
broad sale beat core growth ep ahead
revenu y/i ahead our/street est
management quot pro forma organ sale growth number incl euroimmun core
contribut underli clean core growth well vs estimate fx
sale in-lin vs estimate euroimmun
double-digit organ growth non-gaap gm
estimate adj opm ahead larg tie top-lin volum
fx off-set adj ep vs guid street estimate
anoth rais fy outlook pure beat
demand broad-bas product segment custom group discoveri
analyt solut da grew organ led double-digit lifesci growth
demand pharma academ government custom demand
appli market food environment industri high singl digit hsd
diagnost dx legaci core growth hsd reproduct health strong dd
growth genom immunodiagnost geographi grew asia europ
dd america hsd rais organ fy guid
includ euroimmun organ contribut compris da dx
although smaller fx vs prior vs prior
tailwind off-set organ boost notabl organ rais includ
improv outlook management indic caution warrant due
global macro/trad environ bottom line adj ep guid rais
beat lower tax-rat smaller fx
updat estim stay neutral po
overal strong quarter aid easi comp organ
conserv outlook lead us reiter neutral rate await
clariti pki new growth profil beyond ie still somewhat
skeptic deliv hsd core growth adjust revenu
est rais ep estimate vs prior po goe
still ep higher ep estim
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
price object base ep estim
in-lin compani broader lst diagnost peer group two year
forward multipl signific premium histor multipl due
improv core growth margin feel multipl appropri given
on-going oper improv improv growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani downsid risk competit execut integr risk
weaker macro environ fx swing fund cut slower expect
uptak new product regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
